19 November 2017
News and Views
Links and Services
Patients with chronic hepatitis B treated with oral antiviral therapy retain a higher risk for HCC compared with patients with inactive stage disease, reports the latest issue of Gut.
It is generally stated that oral antiviral therapy in patients with chronic hepatitis B decreases
Email this page to a colleague
GastroHep.com is a Blackwell Publishing registered trademark
© 2017 Wiley-Blackwell and GastroHep.com and contributors